By: Patrick Lavery
Editor's Take: Billions are being spent on mergers, acquisitions, and development and commercialization deals for cutting-edge drugs.
Patrick Lavery is an Editor for the MJH Life Sciences brands Pharmaceutical Technology and BioPharm International. He specializes in topics such as gene therapy, pharmaceutical manufacturing, and regulation, as well as digital health and telehealth advancements. Patrick's work has been featured in LCGC, Spectroscopy Media, New Jersey 101.5 Radio, BioPharm International, PharmTech, The National Law Review, JD Supra, Contract Pharma, and Pharmaceutical Executive.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston


Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .